GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » Cyclically Adjusted PB Ratio

Zevra Therapeutics (FRA:1GDA) Cyclically Adjusted PB Ratio : (As of May. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zevra Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Zevra Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Cyclically Adjusted PB Ratio Chart

Zevra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zevra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zevra Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Zevra Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zevra Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's Cyclically Adjusted PB Ratio falls into.



Zevra Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Zevra Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Zevra Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.073/131.7762*131.7762
=1.073

Current CPI (Mar. 2024) = 131.7762.

Zevra Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -51.141 99.070 -68.024
201503 -65.287 99.621 -86.360
201506 3.470 100.684 4.542
201509 -5.752 100.392 -7.550
201512 -10.259 99.792 -13.547
201603 -11.379 100.470 -14.925
201606 0.323 101.688 0.419
201609 -9.541 101.861 -12.343
201612 -19.361 101.863 -25.047
201703 -34.654 102.862 -44.395
201706 -38.159 103.349 -48.655
201709 -44.052 104.136 -55.745
201712 -53.053 104.011 -67.215
201803 -68.453 105.290 -85.673
201806 -71.942 106.317 -89.170
201809 -81.497 106.507 -100.833
201812 -35.388 105.998 -43.994
201903 -37.877 107.251 -46.539
201906 -40.013 108.070 -48.790
201909 -31.678 108.329 -38.534
201912 -29.495 108.420 -35.849
202003 -17.520 108.902 -21.200
202006 -13.286 108.767 -16.097
202009 -11.676 109.815 -14.011
202012 -12.032 109.897 -14.427
202103 2.485 111.754 2.930
202106 3.101 114.631 3.565
202109 3.171 115.734 3.611
202112 3.214 117.630 3.601
202203 3.205 121.301 3.482
202206 2.722 125.017 2.869
202209 2.746 125.227 2.890
202212 2.053 125.222 2.160
202303 1.968 127.348 2.036
202306 1.864 128.729 1.908
202309 1.746 129.860 1.772
202312 1.366 129.419 1.391
202403 1.073 131.776 1.073

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zevra Therapeutics  (FRA:1GDA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Zevra Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zevra Therapeutics (FRA:1GDA) Business Description

Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines